auto-fix: address review feedback on 2026-01-29-varda-w5-reentry-success.md

- Fixed based on eval review comments
- Quality gate pass 3 (fix-from-feedback)

Pentagon-Agent: Astra <HEADLESS>

domains/space-development/the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure.md

@@ -15,7 +15,7 @@ secondary_domains:
 
 The space manufacturing economy will not be built on a single product. It will be built on a portfolio of high-value-per-kg products that collectively justify infrastructure investment in sequence, where each tier catalyzes the orbital capacity the next tier requires.
 
-**Tier 1: Pharmaceutical crystallization (NOW, 2024-2027).** This is a present reality. Varda Space Industries has completed four orbital manufacturing missions with $329M raised and monthly launch cadence targeted by 2026. The Keytruda subcutaneous formulation — directly enabled by ISS crystallization research — received FDA approval in late 2025 and affects a $25B/year drug. Pharma crystallization proves the business model: frequent small missions, astronomical revenue per kg (IP value, not raw materials), and dual-use reentry vehicle technology. Market potential: $2.8-4.2B near-term. This tier creates the regulatory and logistical frameworks that all subsequent manufacturing requires.
+**Tier 1: Pharmaceutical crystallization (NOW, 2024-2027).** This is a present reality. Varda Space Industries has completed five orbital manufacturing missions with $329M raised and monthly launch cadence targeted by 2026. The Keytruda subcutaneous formulation — directly enabled by ISS crystallization research — received FDA approval in late 2025 and affects a $25B/year drug. Pharma crystallization proves the business model: frequent small missions, astronomical revenue per kg (IP value, not raw materials), and dual-use reentry vehicle technology. Market potential: $2.8-4.2B near-term. This tier creates the regulatory and logistical frameworks that all subsequent manufacturing requires.
 
 **Tier 2: ZBLAN fiber optics (3-5 years, 2027-2032).** ZBLAN fiber produced in microgravity could eliminate submarine cable repeaters by extending signal range from 50 km to potentially 5,000 km. A 600x production scaling breakthrough occurred in 2024 with 12 km drawn on ISS. Unlike pharma (where space discovers crystal forms that might eventually be approximated on Earth), ZBLAN's quality advantage is gravitational and permanent — the crystallization problem cannot be engineered away. Continuous fiber production creates demand for permanent automated orbital platforms. Revenue per kg ($600K-$3M) vastly exceeds launch costs even at current prices. This tier drives the transition from capsule-based missions to permanent manufacturing infrastructure.
 
@@ -25,13 +25,12 @@ The space manufacturing economy will not be built on a single product. It will b
 
 ## Challenges
 
-Each tier depends on unproven assumptions. Pharma depends on some polymorphs being truly inaccessible at 1g — advanced terrestrial crystallization techniques are improving. ZBLAN depends on the optical quality advantage being 10-100x rather than 2-3x — if the advantage is only marginal, the economics don't justify orbital production. Bioprinting timelines are measured in decades and depend on biological breakthroughs that may take longer than projected. The portfolio structure partially hedges this — each tier independently justifies infrastructure that de-risks the next — but if Tier 1 fails to demonstrate repeatable commercial returns, the entire sequence stalls. Confidence is experimental rather than likely because the thesis is conceptually sound but only Tier 1 has operational evidence (Varda's four missions), and even that is pre-revenue.
+Each tier depends on unproven assumptions. Pharma depends on some polymorphs being truly inaccessible at 1g — advanced terrestrial crystallization techniques are improving. ZBLAN depends on the optical quality advantage being 10-100x rather than 2-3x — if the advantage is only marginal, the economics don't justify orbital production. Bioprinting timelines are measured in decades and depend on biological breakthroughs that may take longer than projected. The portfolio structure partially hedges this — each tier independently justifies infrastructure that de-risks the next — but if Tier 1 fails to demonstrate repeatable commercial returns, the entire sequence stalls. Confidence is experimental rather than likely because the thesis is conceptually sound but only Tier 1 has operational evidence (Varda's five missions), and even that is pre-revenue.
 
-
-### Additional Evidence (challenge)
+## Additional Evidence (challenge)
 *Source: [[2026-01-29-varda-w5-reentry-success]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
 
-**Temporal overlap evidence (2026-01-29):** Varda opened a 10,000 sq ft biologics lab in El Segundo in 2026 specifically for monoclonal antibody processing, which is a complex biologics capability that straddles the pharmaceutical and bioprinting tiers. This suggests the tier boundaries may be more overlapping than strictly sequential—companies may develop capabilities across multiple tiers simultaneously rather than waiting for one to mature before starting the next. The economic logic (each tier funds the next through revenue) may still hold, but the temporal execution appears to be overlapping development rather than strict succession. Varda's AFRL Prometheus contract provides government revenue to fund biologics R&D without waiting for pharmaceutical revenue to scale first, enabling parallel tier development. However, this is based on announced intent and lab opening, not demonstrated orbital biologics processing, so the claim remains speculative.
+**Temporal overlap evidence (2026-01-29):** Varda opened a 10,000 sq ft biologics lab in El Segundo in 2026 specifically for monoclonal antibody processing, which is a complex biologics capability that straddles the pharmaceutical and bioprinting tiers. This suggests the tier boundaries may be more overlapping in execution than strictly sequential—companies may develop capabilities across multiple tiers simultaneously rather than waiting for one to mature before starting the next. The economic logic (each tier funds the next through revenue) may still hold, but the temporal execution appears to be overlapping development rather than strict succession. Varda's AFRL Prometheus contract provides government revenue to fund biologics R&D without waiting for pharmaceutical revenue to scale first, enabling parallel tier development via alternative bootstrap mechanisms (government demand floors rather than commercial revenue). However, this is based on announced intent and lab opening, not demonstrated orbital biologics processing, so the claim remains speculative. This enrichment suggests the three-tier sequence is robust as an economic model but may execute with more temporal overlap than the original thesis implied, especially when government contracts provide alternative funding mechanisms.
 
 ---
 

domains/space-development/varda-space-biologics-development-blurs-three-tier-manufacturing-sequence.md

@@ -2,20 +2,20 @@
 type: claim
 domain: space-development
 secondary_domains: [health]
-description: "Varda's monoclonal antibody processing starting in 2026 suggests the pharma and bioprinting tiers of space manufacturing are overlapping rather than strictly sequential"
+description: "Varda's monoclonal antibody processing starting in 2026 suggests companies may pursue parallel tier development in space manufacturing, decoupling capability advancement from the revenue-sequencing model"
 confidence: experimental
 source: "Varda Space Industries PR (2026-01-29), new biologics lab opening"
 created: 2026-01-29
 depends_on: ["the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure"]
 ---
 
-# Varda's biologics development suggests the three-tier space manufacturing sequence is overlapping rather than strictly sequential
+# Varda's biologics development suggests companies may pursue parallel tier development in space manufacturing
 
 The existing three-tier thesis positions bioprinted organs as a 15-25 year horizon following pharmaceuticals and ZBLAN fiber, implying a sequential progression where each tier matures before the next begins. However, Varda opened a 10,000 sq ft biologics lab in El Segundo in 2026 specifically for monoclonal antibody processing—a capability that straddles the pharmaceutical and bioprinting tiers.
 
 Monoclonal antibodies represent a complexity tier above small-molecule crystallization (ritonavir) but below full tissue engineering. They require precise protein folding and cellular expression systems in microgravity, capabilities closer to bioprinting than to simple pharmaceutical crystallization. This suggests companies may develop capabilities across multiple tiers simultaneously rather than waiting for one to mature before starting the next.
 
-The economic logic of the three-tier sequence may still hold (each tier funds the next through revenue), but the temporal execution appears to be overlapping development rather than strict succession. Varda's AFRL Prometheus contract provides government revenue to fund biologics R&D without waiting for pharmaceutical revenue to scale first, enabling parallel tier development.
+The mechanism enabling parallel development is government contract funding. Varda's AFRL Prometheus contract provides a revenue floor independent of commercial pharmaceutical revenue, allowing the company to fund biologics R&D without waiting for Tier 1 (pharma) to generate sufficient commercial returns. This decouples capability development from the revenue-sequencing model described in the original three-tier thesis. The economic logic of the sequence may still hold (each tier eventually funds the next through revenue), but the temporal execution can be overlapping when government demand floors provide alternative bootstrap mechanisms.
 
 ## Evidence
 - Varda opened 10,000 sq ft biologics lab in El Segundo for monoclonal antibody processing (PR Newswire, 2026-01-29)
@@ -24,14 +24,14 @@ The economic logic of the three-tier sequence may still hold (each tier funds th
 - AFRL Prometheus multi-year IDIQ contract secures reentry flights through at least 2028, providing revenue floor for biologics R&D independent of commercial pharmaceutical revenue
 
 ## Limitations
-This is based on announced lab opening and stated intent, not demonstrated orbital biologics processing. Monoclonal antibody development may be exploratory rather than production-ready. The three-tier sequence may still hold as a revenue/scale progression even if capabilities develop in parallel.
+This is based on announced lab opening and stated intent, not demonstrated orbital biologics processing. Monoclonal antibody development may be exploratory rather than production-ready. The three-tier sequence may still hold as a revenue/scale progression even if capabilities develop in parallel. This claim describes one company's execution pattern enabled by government contracts, not a universal shift in how space manufacturing tiers develop. The evidence is specific to Varda and AFRL; generalization to the broader industry would require additional cases.
 
 ---
 
 Relevant Notes:
 - [[the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure]]
-- [[Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026]]
-- [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]]
+- [[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]
+- [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] <!-- claim pending -->
 
 Topics:
 - [[domains/space-development/_map]]

domains/space-development/varda-vertical-integration-reduces-space-manufacturing-access-costs.md

@@ -2,7 +2,7 @@
 type: claim
 domain: space-development
 description: "In-house satellite bus and heatshield production enables Varda to reduce per-mission costs and accelerate reentry vehicle iteration cycles"
-confidence: likely
+confidence: experimental
 source: "Varda Space Industries W-5 mission (2026-01-29), vertical integration debut"
 created: 2026-01-29
 depends_on: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"]
@@ -24,13 +24,12 @@ The W-series cadence provides evidence of the payoff: 4 launches in 2025 alone,
 - [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]]
 
 ## Limitations
-This claim infers cost reduction from vertical integration and cadence acceleration, but does not cite specific per-mission cost data or manufacturing cost breakdowns. The causal link between vertical integration and cadence is plausible but not directly demonstrated in the source material.
+This claim infers cost reduction from vertical integration and cadence acceleration, but does not cite specific per-mission cost data or manufacturing cost breakdowns. The causal link between vertical integration and cadence is plausible but not directly demonstrated in the source material. Varda's scale is orders of magnitude smaller than SpaceX's; the same compounding effects may not materialize at their current operational level. This is rated `experimental` rather than `likely` because the mechanism is sound but cost reduction remains inferred rather than demonstrated.
 
 ---
 
 Relevant Notes:
 - [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]]
-- [[Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026]]
 - [[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]
 
 Topics: